Dr. Dae Wook Lee | Cardiovascular Pharmacology | Editorial Board Member

Takeda Pharmaceuticals Asia-Pacific | South Korea

Dr. Dae Wook Lee is a senior medical leader serving as Head of Medical Portfolio Management for Rare Disease, Gastroenterology, Plasma-Derived Therapies, Neuroscience, and New Molecular Entities across the Asia-Pacific region at Takeda Pharmaceutical Ltd Pte. With a strong academic foundation that includes a medical degree from the University of Warwick and advanced training in genetic epidemiology and biomedical science, he brings a rigorous scientific perspective to therapeutic development and strategic medical affairs. His clinical research interests center on the genetic underpinnings and innovative analytical approaches relevant to rare diseases, spanning rare hematologic conditions, metabolic disorders such as Fabry and Gaucher diseases, immunologic conditions including hereditary angioedema, and complex neurodevelopmental disorders such as pediatric epilepsy and narcolepsy type 1. In addition, he maintains a strong focus on the etiology and pathophysiology of inflammatory bowel disease, contributing to the advancement of targeted therapies in gastroenterology. Dr. Lee has authored impactful research, including a network meta-analysis evaluating the comparative efficacy and safety of angiotensin II receptor blocker and amlodipine combination therapy in Asian patients with hypertension, as well as a real-world evidence study in ulcerative colitis using exploratory propensity score matching to refine clinical insights. His dedication to scientific advancement is further reflected in his active involvement with the Korean Society of Pharmaceutical Medicine, where he contributes to ongoing innovation in pharmaceutical research and medical strategy.